





# Investor Presentation

ProPhaseLabs.com


**NASDAQ: PRPH**



# FORWARD LOOKING STATEMENTS

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our plans to grow our subsidiaries and build a multi-billion dollar company, our expected timeline for commercializing our BE-Smart Test and its market potential and our belief in Project ZenQ-AI's potential to contribute to the identification of novel, actionable targets for cancer therapies. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

# OUR BEST IS YET TO COME! PERFORMANCE TRACK RECORD





**Pharmaloz**  
Manufacturing, Inc.



# WHAT IS PHARMALOZ MANUFACTURING?

**Pharmaloz Manufacturing is a full-service manufacturer and private label developer of a broad range of non-GMO, organic and natural-based cough drops and lozenges, and over-the-counter (“OTC”) drug and dietary supplement products.**

Manufacturing for 35 years, and is one of the largest lozenge manufacturing facilities and Contract Development and Manufacturing Organization (CDMO), wholly owned by ProPhase Labs in Lebanon, PA.

Pharmaloz partners with brokers and retailers and our suppliers provide us with top-quality ingredients that extend to our customers to provide superior products.

Manufactures for some of the largest brands.

# THE PHARMALOZ MANUFACTURING FACILITY

**One of the Largest Lozenge Manufacturer in the U.S.**

**Lozenge Contract Manufacturing** - 60,000 sq. ft. climate-controlled facility on 12 acres operating under FDA 21 CFR 210 & 211 guidelines provides the ability to offer products for diversified needs.

**Research & Development** - Works to develop and formulate customers' unique, best in class products

**Marketing** - Offers the ability to deploy various strategies to help customers market their products successfully.

**Shipping, packing and distribution logistics** - able to service over 40,000 food, drug and mass stores in the United States.

**Quality & Regulatory** - Embraces the importance of both Quality & Regulatory compliance throughout the manufacturing process.



# GROWING CUSTOMERS AND EXPANDING PRODUCTION CAPACITY AHEAD OF SCHEDULE

## Aggressive expansion commenced Q3 2023

**Current demand greater** than max capacity and growing significantly. Increased prices on all customers effective Q1 2024. Pharmaloz turns profitable in Q1 2024.

**Automation increased plant capacity** from below \$10 million to over \$15 million annualized revenue\*. Goal: 20-25% net profit margins.

**Additional lozenge line to be installed** end of Q2 2024 with the goal of tripling new capacity during Q3 2024\*\*.

**NEW CAPACITY ESTIMATE \$45 MILLION IN Q3\*\***

**Signed two top-tier lozenge brands adding** an additional \$5m annualized revenues with significant profit margins\*.

**Two additional large global brands,** currently in late stage discussions.

**Additional lozenge lines on order** set to arrive by Q4 2024

**Goal is to add additional production lines** to increase capacity to \$80-\$100 million annualized revenues by mid 2025\*.



\*Management's analysis and guidance announced by ProPhase Labs on January 23, 2024: <https://www.globenewswire.com/en/news-release/2024/01/23/2814037/0/en/Pharmaloz-Manufacturing-Accelerates-Expansion-Improves-Pricing-Boosts-Profitability-and-Secures-New-Contracts.html>

\*\*<https://finance.yahoo.com/news/prophase-labs-announces-financial-results-120000611.html>

# TK SUPPLEMENTS®

A line of dietary supplements dedicated to providing clinically tested products for men's sexual health that we develop and market.




## LEGENDZ XL®

For male sexual enhancement.  
Event based; clinically proven to promote blood flow in < 60min with first use.



## TRIPLE EDGE XL®

A daily energy and stamina booster  
Daily support; clinically proven to improve physical and mental energy while promoting healthy testosterone levels.



## SUPER PROSTAFLOW+™

A supplement to support prostate and urinary health.





**Nebula  
Genomics**

# MEET GEORGE CHURCH, FOUNDER OF NEBULA GENOMICS AND SCIENTIFIC ADVISOR

**Mission: To usher in the era of personal genomics by providing access to affordable and secure Whole Genome Sequencing.**


Nebula Genomics turns these breakthrough technologies into B2C and B2B products available around the globe.

**Prof. George Church**, co-founder of Nebula Genomics; Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard University and the Massachusetts Institute of Technology (MIT).

**Contributed to the development of multiple DNA sequencing methods.** In particular, molecular multiplexing approaches that enabled next-generation DNA sequencing as well as long-read nanopore sequencing.

**Initiated the Personal Genome Project** whose pioneering work contributed to the development of DNA sequencing and genome engineering technologies for which he received multiple awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

**Co-authored over 550 publications; more than 150 patents;** authored the book, “Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves”; started over 20 companies.



**"Genome sequencing is like the internet back in the late 1980s."**

George M. Church  
Professor - Harvard and MIT  
Co-founder - Nebula Genomics

# WHOLE GENOME SEQUENCING (WGS)

The Key to Unlocking True Personalized Medicine


**WGS technology obtains comprehensive data on every gene and chromosome in your DNA.** Our WGS DNA test analyzes greater than 99% of your DNA compared to typical (SNP) Single Nucleotide Polymorphism – based ancestry tests that analyze less than 1% of your DNA, at a competitive price. Our WGS offers deep health-related insights that are not possible with SNP-based tests. Can be used to examine ancestry, health, diet, rare gene mutations and potential predispositions to disease.

Large WGS database with specimens from over 120 countries globally. The database is the equivalent of approximately 150 million SNP-based ancestry tests, while collecting deep genetic information that SNP-based tests cannot collect.

Proprietary library with over 300 reports leveraging the proprietary database. Regularly updated with genetic research articles and studies.

## The Nebula Membership includes:

- ✓ **330+ personal genomic scores that provide insights into your personal genetic makeup**
- ✓ **New scores every month**
- ✓ **Thorough explanations of research findings – updated regularly**
- ✓ **Ancestry report & add-on deep ancestry report**
- ✓ **Oral Microbiome Test**
- ✓ **Gene Analysis Tool \***



\* Nebula Gene Analysis is a user-friendly platform that explores genes and how they impact our health. It uses trusted health databases to make complex genetic information easy to understand, ensuring the data you see is accurate and reliable. Whether you're curious about your own genetic makeup or just interested in genetics, this tool opens up the science of genes to everyone.

# WHAT DO YOU WANT TO LEARN FROM WHOLE GENOME SEQUENCING (WGS)?

**We are one of the leading WGS providers** with high accuracy, high quality, and competitive pricing.

**Offering deep insights for customers,** universities, and the healthcare industry with some of the best-in-class tools and interpretation capabilities.

**Learn what your DNA says about your ancestry,** with the most accurate genetic test that decodes 100%\* of your DNA.

**We currently offer Nebula Genomics whole genome sequencing products direct-to-consumers** online.

Immediate plans to build B2B, including telemedicine platforms, universities conducting genomic research, global testing distribution companies, etc.

**1** Learn about your ancestry and find new relatives

**2** Decode all your genes and identify mutations

**3** Get full access to your genomic big data

**4** Determine appropriate diet and supplementation

**5** Find the right exercise plan to lose weight

**6** Learn more about the genetics of your mind, behavior, and personality

**7** Learn how genomic research applies to your test results

**8** Uncover your oral microbiome

# INSIGHTS + TOOLS + REAL WORLD APPLICATION

Nebula Library digests global genetic research and keeps you informed regularly about the latest genomic discoveries and advances in medicine.

Learn how research in personalized precision medicine might be relevant to your health and well-being!

Thorough explanations of research findings – updated regularly

Personal genomic scores that provide insights into your personal genetic makeup

Based on your personal sequencing results.

09/2019

★ Gastroesophageal reflux disease (An, 2019) [🔗](#)

Stomach Cancer

#### STUDY SUMMARY

Identification of 25 genetic loci that are associated with an increased risk of gastroesophageal reflux disease.

#### YOUR RESULT



#### STUDY DESCRIPTION

Gastroesophageal reflux disease (GERD) occurs when stomach acid flows up into the esophagus, or food pipe. This acid irritates the lining of the esophagus, and over time can lead to an increased risk of esophageal cancer. While nearly a third of an individual's risk of developing GERD is believed to be heritable, no genetic loci that are linked to GERD have been identified to date.



[View Full Report](#)

1/2020


★ Breast cancer (Fachal, 2020) [🔗](#)

Cancer Breasts

#### STUDY SUMMARY

Identification of 206 genetic variants associated with a risk of developing breast cancer.

#### YOUR RESULT



#### STUDY DESCRIPTION

Breast cancer is currently the second most common cancer among women (behind skin cancer), affecting nearly 1 in 8 during their lifetime. Nearly 10% of all cases of breast cancer are thought to be hereditary.

[View Full Report](#)

*For research, information and educational use only*

# NEBULA GENOMICS ROADMAP

## Low-cost provider of DTC WGS

- (DTC) Direct to consumer
- 73% Global market penetration
- Goal: FDM retail stores

## Low-cost provider of B2B WGS – currently research use only with clinical grade data.

### B2B partners include:

- Academic Research Centers
- Clinical Research Organizations
- Pharmaceutical Companies
- Physicians' offices
- Telemedicine platforms
- Healthcare Systems
- U.S. and international clients
- Longevity clinics
- Labs without internal sequencing

## Nebula Library: Genomic Information with exploration tools

- High margin subscription model with high long-term customer value
- Continuous access to sequencing reports
- Confidentially secured data

## SIGNIFICANT NEBULA ASSETS



### NYS DOH CLIA/CLEP Accredited Laboratory\*

*Illumina, BGI/MGI, and Element Biosciences*



### Platform Agnostic

### Strong Brand Equity - Globally

*Featured in WSJ, NY Times, Wired, MIT Technology Review, Nature*



### Advisory Board Key Opinion Leaders

*George Church, Harvard Medical School  
Russ Altman, Stanford University  
Patrick Merel, Genomics Professional*



### 100,000 Robust Data Sets

*Specimens from 120+ countries, B2B clients*



### 40,000+ WGS plus 60,000 Snips

*The snips come from consumers uploading their data to get small sample report which captures less than 1% of your DNA. The WGS captures 100% DNA*

\* NYS DOH – New York State Department of Health; CLIA - Clinical Laboratory Improvement Amendment of 1988; CLEP – Clinical Laboratory Evaluation Program

# NEBULA – CURRENT GROWTH UPDATES

## New Consumer DNA Test Set For Release – Q2 2024

**Market Disruptor:** Introducing a whole genome sequencing (WGS) DNA test that analyzes greater than 99% of your DNA compared to typical SNP-based ancestry tests that analyze less than 1% of your DNA, for about the same price. Offering deep health-related insights that are not possible with SNP-based tests. Cost-effective DTC genetic test designed for broad market penetration and consumer accessibility.

**Strategic Alliances:** Collaborating with a premier marketing, growth, and branding firm to amplify reach and adoption.

**Expert-Driven Growth:** Hired senior-level consultant, a former executive of a billion-dollar digital media company to spearhead our DTC strategies and establish influential partnerships.

**Affordability Meets Innovation:** Launching an exceptionally priced WGS product with the cost appeal of traditional ancestry tests, setting a new benchmark for value in genomic testing.

## DNA Upload Product – Exponential Growth

**Seamless Integration:** Users effortlessly upload their DNA data from other ancestry/DNA tests to unlock our proprietary reports and advanced features.

**Unmatched Offer:** Outperforms rivals on price, security, and capabilities—redefining value in the DNA analysis market.

**Organic User Growth:** Scaled to 10,000+ active users with a pure word-of-mouth buzz.

**Aggressive Scale-Up:** Ready to amplify reach with the robust marketing machine that propelling our DTC business lines.

# NEBULA – FUTURE GOALS





Nebula is becoming a dominant technology and software leader in genomics and (BIX) Business Intelligence Exchange, leveraging extensive bioinformatics R&D to revolutionize genomic data analysis.

Our transformative actions include:

- ✓ **SaaS Solutions Launch**: We're introducing a specialized SaaS business line to address the growing need for sophisticated genomic reporting and bioinformatics applications.
- ✓ **Monthly Genomic Reports**: Launching a vast catalog of in-depth genomic reports for our subscribers, positioning us as the preeminent genomic reporting platform worldwide. Our approach emphasizes immediate value, with a wealth of insights ready to be unlocked.
- ✓ **Pharmacogenomics & Nutrigenomics Testing**: Our personalized testing services unlock critical insights into how genetics affect drug responses and the impact of nutrients on health, guiding the path to personalized medicine.
- ✓ **WGS Database Expansion**: We're enhancing our Whole Genome Sequencing database, creating an unmatched resource for research and innovation in genomics.

Nebula is not just leading the charge in genomics and biotech; we're setting new standards for personalized healthcare and genomic exploration.





# ProPhase

BIOPHARMA

# BE-SMART ESOPHAGEAL CANCER TEST

## ESOPHAGEAL ADENOCARCINOMA (EAC) – ONE OF THE DEADLIEST CANCERS

- 16,000+ Estimated Deaths in 2023 in the U.S.<sup>1</sup>
- 78.3% - 5-Year Mortality Rate (2013-2019)<sup>1</sup>
- 21,000+ Estimated New Cases in 2023<sup>1</sup>
- The change in the annual incidence of EAC was 766.67% higher in 2017 compared to 1973<sup>2</sup>
- Journal of American Medical Association once again reported that GI cancers for the 2nd straight decade are the fastest growing cancer type in America<sup>3</sup>

**Gastroesophageal Reflux Disease (GERD)** occurs when stomach acid repeatedly flows back into the esophagus. Backwash (acid reflux) can irritate the lining of esophagus. Many experience acid reflux from time to time; for some, GERD may trigger a change in the cells lining the lower esophagus causing **Barrett's Esophagus**.

**Barrett's Esophagus** - esophagus becomes damaged by acid reflux; causes the lining to thicken and become red. Associated with increased risk of developing **Esophageal Adenocarcinoma**.

Discovering pre-cancerous tissue in early and treatable stages may increase disease survival and decrease cost of care. As high as 40% of esophageal carcinoma is missed or found late leading to more unfavorable diagnosis.



# BE-Smart™ - ESOPHAGEAL PRE-CANCER DIAGNOSTIC

**Intended to detect and quantify early signs of certain types of cancer in individuals with Barrett's esophagus**, a condition known to significantly increase the risk of developing esophageal cancer.

**Mass spectrometry-based diagnostic intended for cancer progression surveillance in Barrett's esophagus patients.** The test is believed to have both high diagnostic and prognostic capabilities to allow health care providers to initiate early treatment, such as an ablation procedure, to remove precancerous cells and significantly reduce unnecessary endoscopies.

**US patent granted safeguarding the BE-Smart technology and extending** protection to similar biomarker discovery processes for patent claims limited to esophageal adenocarcinoma.

**In development as a Laboratory Diagnostic Test (LDT) for ~ five years in collaboration with the Mayo Clinic** and for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.

**Recent studies to date have achieved consistently positive preliminary results.** BE-Smart has demonstrated a greater than 99% accuracy in distinguishing highly impactful and objective histologic classifications. The latest data is under review by an independent statistics company for potential final presentation to insurance companies for CPT codes and near-term commercialization.

**Aiming for initial commercialization in 2024 with the goal of reimbursement rates between \$1,000 - \$2,000.** Subject to successfully completing the testing phase and regulatory compliance.

# OPPORTUNITY TO PREVENT ESOPHAGEAL CANCER

Prevalence of GERD in the U.S  
ranges from 18.1% to 27.8% in North  
America (Census 303 million)<sup>1</sup>

~ **60 million**

Prevalence of Barrett's Esophagus in the  
U.S. is 5.6% of the population (Census  
303 million)

~ **16 million**

New Cases of Esophageal  
Adenocarcinoma in U.S. per year<sup>1</sup>

~ **20K**

Endoscopy (upper) related to GERD  
and Barrett's Esophagus average

~ **7 million**

Endoscopy (upper) related to  
Barrett's Esophagus average<sup>1</sup>

~ **2 million**

Annual Tests ~2-7mm

Average Cost/Test \$1k-\$2k

---

**Total  
Addressable  
Market** ~\$2-\$14bn


<sup>1</sup> - Barrett Esophagus: Rapid Evidence Review | AAHP Gastroesophageal Reflux Disease - StatPearls - NCBI Bookshelf (nih.gov) Esophageal Cancer — Cancer Stat Facts  
U.S. GI Endoscopy Volumes: Biggest Change Is Increases in Upper Endoscopic Ultrasound - Endoscopy Campus (endoscopy-campus.com) Management of Barrett's esophagus -  
American Gastroenterological Association

# EQUIVIR AND EQUIVIR G

**Equivir (OTC) and Equivir G (Rx):** compounds that have demonstrated potential activity against certain viruses associated with serious viral outbreaks. Equivir portfolio is designed to supplement the body and work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells.

**Acquired exclusive, worldwide development and commercial rights developed by Global Research and Discovery Group** - scientific think tank and research organization working with BARDA, DARPA, and the Potomac Institute to provide novel, multi-target therapeutics for challenging pharmacological needs.

**Blend of: Polyphenols, Myricetin, Hesperidin, Piperine.**



# EQUIVIR CLINICAL TRIAL\*\*

## Equivir Clinical Trials with Vedic Lifesciences

Final analysis targeted for completion in Q2 2024. Goal of launching in 2024 as an OTC dietary supplement.

Preliminary results\*: Overall, in the initial 150 patient group, approx. 46 incidences of upper respiratory viral infections. 62.3% of the patients in the placebo group acquired a viral infection versus only 37.7% in the Equivir group.

Additional key statistics from the initial findings are:

- 39% of the placebo population acquired an upper respiratory viral infection vs 22.9% in the Equivir group.
- After 4 days of illness, only 3% of the Equivir group still had mild symptoms vs 55% in the placebo group.
- The average severity was 16% less severe when taking Equivir vs the placebo.
- No patients in the Equivir group became ill a second time while 2 patients in the placebo group had a second upper respiratory viral infection.

\*\*Equivir is being developed with plans to market as an OTC dietary supplement. Therefore, the Company cannot make specific claims regarding Covid-19 [or respiratory viral infection] treatment or prevention and is not seeking the U.S. Food and Drug Administration's approval of Equivir as a drug. However, the Company plans to publish the results when both studies are completed.

\*Preliminary results announced by ProPhase Labs on February 14, 2024: <https://www.globenewswire.com/en/news-release/2024/02/14/2829018/0/en/ProPhase-Labs-Announces-Preliminary-Positive-Results-for-Dietary-Supplement-Equivir.html.html>

# PROJECT ZENQ-AI: LEVERAGING A COMBINATION OF AI PLATFORM, GENOMIC DATABASE AND IP-PATENTED ESOPHAGEAL CANCER INSIGHTS

ProPhase Labs has developed a proprietary AI platform, optimized to integrate and analyze data from two pivotal resources: an extensive genomic database compiled from six years of comprehensive whole genome sequencing tests, and a specialized esophageal cancer database enriched with six years of dedicated research and IP-protected discoveries.

## Technological Foundations

- ✓ AI Platform: developed with cutting-edge AI technologies from leading platforms
- ✓ Hardware utilization: leveraging on-premises NVIDIA hardware alongside major cloud AI services for enhanced data processing capabilities

## Genomic Insights

- ✓ Whole genome sequencing: captures all 3 billion base pairs, providing a full genetic blueprint
- ✓ Database size: extensive genomic data from over 130 countries, equivalent to about 150 million ancestry SNP-based tests

## Innovations in Cancer Therapy

- ✓ Antibody drug conjugates (ADCs): targeting specific cancer cell markers to minimize healthy cell damage
- ✓ BE-Smart test: patented, tested on over 300 human samples with demonstrated high accuracy for early-stage EAC detection

## Data and Efficiency

- ✓ Data comparison: WGS provides up to 30,000 times more genetic data than traditional SNP testing
- ✓ Cost-effectiveness: low operational cost of data analysis through AI, enabling affordable scaling of genomic research

## Future Potential and Impact

- ✓ Early detection and treatment: potential to significantly alter the course of cancer treatment with early and precise targeting
- ✓ Global Reach and Collaboration: data diversity enhances the ability to identify unique genetic markers across different populations

# COMPETENT AND PROVEN EXECUTIVE MANAGEMENT TEAM



**Jed Latkin**  
COO  
ProPhase Labs, Inc.

Jed A. Latkin served as a director and Chief Executive Officer of Navidea from October 2018, until October 2021. Mr. Latkin has more than 28 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a CEO/CFO for numerous healthcare related firms. Mr. Latkin worked for over ten years in Investment Banking at Citigroup, Morgan Stanley and Fleet Boston Robertson Stephens. He also spent five years as a Co-Portfolio Manager for ING Investment Management. Mr. Latkin earned a B.A from Rutgers University and a M.B.A. from Columbia Business School.



**Jason Karkus**  
President  
Nebula Genomics

Jason drove explosive revenue growth at ProPhase Diagnostics, leading multiple areas including sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately \$200 million in revenues since 2021 and manages account managers and customer service reps who offer 24/7 service to exceed customer expectations. Jason now heads up business development for the rapid build-out of ProPhase's Nebula Genomics business.

With a background in sales and development at top real estate firms, Jason is a graduate of the University of Maryland.



**Sergio Miralles**  
EVP/CIO  
ProPhase Labs, Inc.

Sergio Miralles is an experienced IT Leader with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. Sergio is responsible for ensuring a complete end-to-end technology solution that links its lab customers' patient data via an interface to efficiently process and report results.

Previously, Sergio founded and led a successful IT consulting firm overseeing 18 IT consultants. For the last five years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certifications from Cisco, ISC2, and CompTIA.



**Kamal Obbad**  
SVP, Director of  
Sales & Marketing  
Nebula Genomics

Kamal is co-founder of Nebula Genomics. He received his undergraduate degree at Harvard University and did graduate studies in computer science as a Gates-Cambridge Fellow at the University of Cambridge. Prior to founding Nebula, Kamal led teams at Google.

For his work, Kamal has received multiple honors including being named to the Forbes 30 under 30 list.



**Robert A Morse**  
Controller  
ProPhase Labs, Inc.

Prior to ProPhase Labs, Robert served as Global Controller and Chief Accounting Officer at multiple high-growth pre-IPO companies in the FinTech, EdTech and Asset Management sectors. He spent four years at MasterCard Worldwide and 10 years at The McGraw-Hill Companies and Standard & Poor's. He began his career with four years in public accounting including two years with Ernst & Young LLP.



# INVESTMENT HIGHLIGHTS

**Expanding Pharmaloz Manufacturing** - One of the Largest Lozenge Manufacturing Companies in the U.S.

- Aggressively growing capacity to meet strong demand
- Turned profitable in Q1 2024
- Continuously growing customer base as capacity expands
- Anticipate revenues and earnings to continue growing rapidly for the foreseeable future

**Nebula Genomics is Well Positioned to Capitalize** on the Future Growth of Genomics and Personalized Medicine.

- Cutting-edge laboratory, globally competitive pricing, proprietary state-of-the-art bioinformatics reporting system
- Growing genomic database
- Significant direct-to-consumer and business-to-business opportunities

**BE-Smart Esophageal Cancer Test:** multi billion-dollar target market and goal to commercialize H2 2024.

**Equivir (OTC):** clinically studied dietary supplement. Goal to commercialize H2 2024.

**ProPhase Labs Unveils Project ZenQ-AI.** Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.

**A History of Returns** With a Diversified Business Model and potential for expansion that should yield significant value creation in 2024 and 2025.

**Competent and Proven Executive Management Team** for more than a decade.



ProPhaseLabs.com

**TED KARKUS**  
**Chairman & CEO**  
711 Stewart Ave., Suite 200  
Garden City, NY 11530

**INSTITUTIONAL INVESTOR RELATIONS**  
267-880-1111  
[investorrelations@prophaselabs.com](mailto:investorrelations@prophaselabs.com)

**RETAIL INVESTOR RELATIONS**  
John Boidman  
Renmark Financial Communications  
514-939-3989  
[jboidman@renmarkfinancial.com](mailto:jboidman@renmarkfinancial.com)

Thank You

